HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Octreotide (Sandostatin)

A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.

Also Known As:

Sandostatin; Octreotide Acetate; Compound 201-995; Octreotide Acetate Salt; SAN 201-995; SM 201-995; SMS 201-995; Sandostatine; Sandoz 201-995; Compound 201 995; Compound 201995; SAN 201 995; SAN 201995; SM 201 995; SM 201995; SMS 201 995; SMS 201995; Sandoz 201 995; Sandoz 201995; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-

Networked: 4121 relevant articles (689 outcomes, 772 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Colao, Annamaria: 21 articles (06/2015 - 01/2003)
2.	Colao, A: 21 articles (03/2015 - 01/2000)
3.	Krenning, Eric P: 17 articles (05/2014 - 04/2002)
4.	Pivonello, Rosario: 15 articles (04/2011 - 01/2003)
5.	Gadelha, Mônica R: 14 articles (12/2015 - 03/2004)
6.	Lombardi, Gaetano: 14 articles (04/2011 - 01/2003)
7.	Yao, James C: 13 articles (12/2015 - 10/2005)
8.	Ferone, D: 13 articles (05/2012 - 04/2000)
9.	de Jong, Marion: 12 articles (05/2014 - 01/2003)
10.	Reubi, Jean Claude: 12 articles (03/2013 - 05/2002)

Related Diseases

1.	Neoplasms (Cancer) 04/01/1989 - "These data suggest that the therapeutic efficacy of octreotide may be related to tumor SRIH receptor levels; the best in vivo responses to octreotide occurred in patients whose tumors contained a high density of homogeneously distributed receptors which had a high affinity for octreotide." 07/01/2009 - "Available evidence indicates that this hybrid imaging technology will become the gold standard for conventional scintigraphy, including bone imaging performed for staging malignancy, and also for the so-called tumor scintigraphies that visualize neoplastic foci via tumor-specific agents such as octreotide labeled with (111)In or (131)I. Another important indication for SPECT/CT is sentinel lymph node scintigraphy, where SPECT/CT fusion helps considerably in localizing the first lymph node draining a tumor. " 02/01/1998 - "No difference in the pretreatment uptake of octreotide by the primary tumor was identified between patients with tumor progression and those with partial or complete remission. " 11/01/1992 - "Two patients whose serum alpha-subunit level did not significantly change while receiving octreotide had a reduction in tumor size or definite improvement in visual field abnormalities. " 06/01/2001 - "In these tumors, octreotide scintigraphy is superior to any other staging method. "
2.	Acromegaly 05/01/2009 - "This first randomized study in unselected patients indicates that the 48-week treatment outcome of octreotide LAR as first-line treatment of acromegaly does not significantly differ from surgery. " 08/01/2009 - "High-dose octreotide treatment is safe and effective (normalisation of IGF1 levels) in a subset of patients with active acromegaly inadequately controlled with long-term SSA. " 07/01/2010 - "Critical appraisal of a randomized trial: surgery is superior to octreotide LAR in newly diagnosed patients with acromegaly." 10/01/2000 - "Octreotide LAR proved effective for the treatment of acromegaly and was well tolerated. " 11/01/1995 - "Sandostatin-LAR is an effective and well-tolerated treatment for patients with acromegaly. "
3.	Diarrhea 06/01/1995 - "Octreotide is very effective in controlling RRT diarrhea. " 09/01/2007 - "Administration of octreotide was effective in relieving his secretory diarrhea. " 12/01/2006 - "Long-acting octreotide is effective in the treatment of severe diarrhea in patients after pelvic pouch surgery." 06/01/1998 - "The demonstrated safety and efficacy of octreotide in this patient population support further investigation of this therapeutic strategy for GVHD-induced diarrhea. " 06/01/1998 - "In this pilot study, octreotide treatment was effective in reducing the amount of diarrhea in patients with acute GVHD. "
4.	Carcinoid Tumor (Carcinoid) 08/01/1995 - "Octreotide has proven therapeutically effective in carcinoid syndrome, but the rarity of carcinoid tumors has hampered detailed dose-ranging studies. " 10/01/2008 - "Octreotide has proven to be an effective agent for symptoms of carcinoid syndrome. " 12/01/2000 - "Octreotide was initiated, resulting in marked improvement in carcinoid symptoms. " 01/01/1991 - "Complete remission of the tumour by low-dose (2 x 100 micrograms daily) octreotide was observed in one carcinoid patient. " 06/01/2003 - "Short term and long term therapy with octreotide significantly improves survival and reduces the severity of 'carcinoid crises'. "
5.	Hemorrhage 07/01/2013 - "We conclude that octreotide treatment in patients with esophageal variceal hemorrhage can result in a significant decrease of dominant power, which correlates with the hemostatic efficacy of octreotide, so the change of dominant power could be used as a predictor of evaluating the treatment efficacy of octreotide in esophageal variceal hemorrhage patients. " 09/01/2002 - "Octreotide appeared to be more effective in controlling acute bleeding in patients with hypertensive gastropathy, with significantly rapid action, smaller transfusion requirements, and minor side-effects. " 10/01/2004 - "These results suggest that octreotide is effective in the treatment of esophageal variceal bleeding and it is a valuable adjuvant treatment in association with endoscopic management." 05/01/1997 - "In randomized controlled trials octreotide has been effective in halting initial hemorrhage and in preventing reoccurrence of bleeding. " 10/01/2004 - "Octreotide was found to be effective regarding hemostasis at 48 hours and on day 7 after the index bleeding episode. "

Related Drugs and Biologics

1.	Somatostatin (Somatotropin Release-Inhibiting Factor)
2.	lanreotide (Somatuline)
3.	Somatostatin Receptors (Somatostatin Receptor)
4.	Octreotide (Sandostatin)
5.	Hormones
6.	Thyrotropin (Thyroid-Stimulating Hormone)
7.	Insulin (Novolin)
8.	Growth Hormone (Somatotropin)
9.	Insulin-Like Growth Factor I (IGF-1)
10.	everolimus

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Sclerotherapy
3.	Injections
4.	Palliative Care (Palliative Medicine)
5.	Pancreaticoduodenectomy